Clinical Research Directory
Browse clinical research sites, groups, and studies.
BEst Size for Ovulation Triggering in Poseidon 4 Patients (BEST 4 Study)
Sponsor: Centrum Clinic IVF Center
Summary
This observational clinical study aims to determine the optimal timing of ovulation triggering in women aged 35 and above with poor ovarian reserve. For this purpose, cases undergoing ovarian stimulation for assisted reproductive treatment and planned final oocyte triggering will be evaluated in two separate groups: 1. \*\*Experimental Group\*\*: Final oocyte triggering will be performed when the follicle or follicles measure between 13-16 mm. 2. \*\*Control Group\*\*: Final oocyte triggering will be performed when the follicle or follicles measure greater than 17 mm. All triggers will be administered uniformly with 6500 units of recombinant hCG and 0,2 mg triptorelin injections. The primary outcome of the study will be the number of mature oocytes. Secondary outcomes will include fertilization rates, embryo counts, and implantation rates. Primary and secondary outcomes will be compared between the two groups.
Official title: What Should Be The Optimal Ovulation Triggering Size in Poseidon Group 4 Patients Undergoing Ovarian Stimulation?
Key Details
Gender
FEMALE
Age Range
35 Years - 44 Years
Study Type
OBSERVATIONAL
Enrollment
200
Start Date
2026-03-15
Completion Date
2026-12-30
Last Updated
2026-03-19
Healthy Volunteers
No
Conditions
Interventions
Ovulation Trigger Timing Based on Leading Follicle Size in POSEIDON Group 4 IVF Patients
In this study, ovulation trigger timing is determined according to the diameter of the leading follicle measured by transvaginal ultrasound during ovarian stimulation in women classified as POSEIDON group 4. Patients undergoing controlled ovarian stimulation are monitored with serial ultrasound examinations and serum hormone measurements. Ovulation triggering is performed when the leading follicle reaches predefined size categories. The study evaluates the association between the diameter of the leading follicle at the time of trigger and reproductive outcomes. The primary outcome measure is the number of metaphase II (MII) oocytes retrieved, while secondary outcomes include blastocyst formation and pregnancy outcomes.
Locations (1)
Centrum Clinic IVF Center
Ankara, Ankara, Turkey (Türkiye)